Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer.
Rea LevickiMartina Lovrić BenčićIrena Ivanac VranešićLada BradićMarta BegovacJuraj JugNatalija Dedić PlavetićPublished in: The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology (2023)
Trastuzumab and trastuzumab emtansine cardiotoxicity manifested as a significant and progressive QTc prolongation after successive drug applications, reaching the peak value just before the fifth cycle of both drugs. Both medications also caused statistically significant but asymptomatic LVEF reduction. Complete reversibility of cardiotoxic effects of both drugs was confirmed by QTc interval and LVEF normalisation after the treatment discontinuation.
Keyphrases
- metastatic breast cancer
- ejection fraction
- epidermal growth factor receptor
- aortic stenosis
- drug induced
- left ventricular
- multiple sclerosis
- positive breast cancer
- tyrosine kinase
- acute myocardial infarction
- transcatheter aortic valve replacement
- mitral valve
- hypertrophic cardiomyopathy
- aortic valve
- coronary artery disease
- cardiac resynchronization therapy
- combination therapy
- replacement therapy
- breast cancer risk